Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban

Table 3 Clinical outcomes at one year in patients undergoing PCI [n(%)]

Variables	Fondaparinux (n = 422)	Enoxaparin (n = 453)	P
MACCE^a	46 (10.9)	57 (12.6)	0.433
Death or MI	18 (4.3)	24 (5.3)	0.475
Death	2 (0.5)	7 (1.5)	0.116
MI	16 (3.8)	17 (3.8)	0.976
TVR	23 (5.5)	28 (6.2)	0.645
Stroke	7 (1.7)	9 (2.0)	0.717
30 day
Major bleeding	1 (0.23)	4 (0.88)	0.429
All bleeding^b	4 (0.95)	13 (2.9)	0.040
1 year
Major bleeding	1 (0.23)	5 (1.1)	0.253
All bleeding^b	10 (2.4)	25 (5.5)	0.018

MI Myocardial infarction, TVR Target vessel revascularization. ^aMACCE: including death from cardiovascular causes, non-fatal myocardial infarction and target vessel revascularization. ^bAll bleeding was defined using the TIMI definition. P < 0.05 was considered to indicate statistical significance

ISSN: 2054-9369